AHR and cancer: Since cancer cells can preferentially up-regulate IDO or TDO, and the release of Kyn is downstream of both pathways, we reasoned that pharmacologic AHR inhibition might lead to superior immune effects, compared with selective IDO or TDO inhibition strategies in controlling IDO/TDO-expressing tumor growth by ensuring that both downstream pathways are blocked (Fig. 4a).